Skip to content

US Dept of Defense – Amyotrophic Lateral Sclerosis (ALS) Research Program

Home / Funding Opportunity / US Dept of Defense – Amyotrophic Lateral Sclerosis (ALS) Research Program

US Dept of Defense – Amyotrophic Lateral Sclerosis (ALS) Research Program

twitterlinkedin

Pilot Clinical Trial AwardHT942524ALSRPPCTA 

  • up to USD$2M over 4 years
  • letters of intent due 24 May 2024
  • Projects may range from phase 1 to small scale Phase 2 trials and should aim to de-risk and inform the design of more advanced trials
  • at least 1 Community Partner must be included in the research team
  • cannot be used for preclinical research studies
  • must address one of the following focus areas:
    • biomarker-driven interventions
    • clinical care
  • Document: Funding Opportunity – HT942524ALSRPPCTA

 

Clinical Outcomes and Biomarkers AwardHT942524ALSRPCOBA 

  • up to USD4750,000 over 3 years
  • letters of intent due 24 May 2024
  • supports development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in ALS
  • at least 1 Community Partner must be included in the research team
  • studies prospectively enrolling patients to collect biospecimens and/or data allowed
  • clinical trials not allowed
  • must address one or both of the following focus areas
    • clinical biomarkers
    • clinical outcomes
  • Document: Funding Opportunity – HT942524ALSRPCOBA

 

Therapeutic Development Award HT942524ALSRPTDA 

  • up to USD$1.5M over 3 years
  • letters of intent due 24 May 2024
  • supports secondary preclinical validation and/or investigational new drug enabling studies of therapeutics
  • applications must have lead compounds in hand and must include proof-of-concept efficacy data in at least one preclinical model system of ALS including whole animal and cellular model systems
  • Document: Funding Opportunity – HT942524ALSRPTDA

 

Therapeutic Idea Award – HT942524ALSRPTIA 

  • up to USD4600,000 over 2 years
  • letters of intent due 24 May 2024
  • supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery.
  • studies are expected to be hypothesis driven and generate preliminary data for future avenues pf therapeutics investigation
  • projects must include an aspect of biomarker development in parallel to the main therapeutic effort
  • preliminary data not required
  • Document: Funding Opportunity – HT942524ALSRPTIA

 

Apply here

Document

ALS Research Program Summary Table: FY24 ALSRP PA Reference Table

You may be also interested in ...